utility estimates. Regression models (tobit, OLS, Censored least absolute deviation) were used to estimate specifi c changes in HRQL associated with the side effects. RESULTS: Many participants reported more than one symptom, with ED most common (n = 139); reduced libido (n = 99); ejaculatory disorder (n = 98), and gynecomastia (n = 20). From the OLS regression EQ-5D and SQoL-3D disutilities were estimated for ED (−0.042; −0.075); reduced libido (−0.053; −0.047); ejaculatory disorder (−0.046; −0.028), and gynecomastia (−0.045; −0.037) respectively. EQ-5D and SQoL-3D were weakly correlated (r = 0.296). CONCLUSIONS: The condition-specifi c and generic estimates indicate the impact of prostate-related preventative treatment on HRQL. While the magnitude of disutilities is similar the poor correlation between the two measures suggests they are measuring different aspects of HRQL. The value of condition-specifi c versus generic methods for estimating utilities will be discussed.
1
Eli Lilly & Company, Indianapolis, IN, USA; 2 Health Research Associates, Inc, Seattle, WA, USA; 3 i3 Research, Basking Ridge, NJ, USA OBJECTIVES: The objective of this qualitative interview study was to assess the content validity of the BII in a sample of men with signs and symptoms of BPH using concept elicitation (CE) and cognitive interviewing (CI) methods. METHODS: Fifty men with BPH participated in the study; 27 completed the CEs and 23 completed the CIs. CEs were semi-structured asking subjects to describe the BPH symptoms they experience and how symptoms impact their life. CIs were semi-structured, asking subjects to describe their 1) diffi culties completing the BII; 2) understanding of item meaning and terminology; 3) understanding of response options; and 4) ability to respond appropriately to the specifi ed recall period. All interviews were audio recorded and transcribed. Data was analyzed using Atlas.ti. a saturation table was used to identify when no new concepts were forthcoming. Inter-rater agreement (IRA) was evaluated by having three coders independently dual-code 3 (11%) transcripts. Consistency of coding was characterized by agreement in the identifi cation of concepts, and agreement in assignment of codes. RESULTS: Saturation of concepts was reached by the completion of 21 CE interviews. High agreement on coding consistency was achieved at 69.4 to 89.4% for identifi cation of concepts, and 87.8 to 96% for assignments of codes. The BII was shown to be readily understandable and easily completed in a short period of time, and supported by the qualitative results as measuring the relevant impacts related to BPH. CONCLUSIONS: The BII shows strong evidence of content validity and provides an assessment of disease-related, clinically meaningful impacts of BPH symptoms and treatment outcomes in BPH studies. is a dyadic (parent and child together) or self-report of ease of use and preference tool that allows objective and normative comparisons across and between injection pens used to administer human growth hormone (hGH). The purpose of this work was to translate and linguistically validate the IPAQ, which was developed in English in the United States, for use in 7 countries: Czech Republic, Germany, The Netherlands, Slovakia, Sweden, Turkey and United Kingdom. METHODS: The IPAQ was translated according to industry standard methodology. Five parent-child dyads (children 8 to 18 years old) per country completed the respective translated questionnaire and participated in a cognitive interview. Interviews were conducted using a standardized guide to assess the relevance, understandability, and appropriateness of the wording of the translations. Qualitative analyses were performed to ensure equivalence and that the content validity of the IPAQ was maintained across language versions. RESULTS: The study sample consisted of 35 parent-child dyads who use injection devices to administer hGH (42.8% male). Mean age of the children was 12 years. The sample consisted of patients who speak 7 languages collectively. All IPAQ items were well understood and proved relevant to the patients in this sample. Of interest, terms such as, "cartridge", "needle guard" and "injecting the medicine" were understood similarly by participants across countries. CONCLUSIONS: The results indicate the IPAQ translations were conceptually equivalent to the English source version and easily understood by the target population in all countries. We consider these translations acceptable for PRO assessment in international research, clinical practice and clinical trials.
PIH35

PIH36 PATIENT SATISFACTION WITH FOLLITROPIN ALFA PREFILLED PEN IN WOMEN UNDERGOING OVARIAN STIMULATION: ELABORATION AND VALIDATION OF VENUSF QUESTIONNAIRE
Espallardo O 1 , Ruiz-Balda J 2 , Carrera M 2 , Caballero J 3 , Polanco C 1 , Bruna I 4 , Hernández C 5 , Cuadrado C 6 , Carrillo E 7 , Ordóñez D 7 , García-Velasco J 8 , Serna J 8 , Galera F 9 , Zafra J 10 , Caballero P 11 , Hernández E 3 , Fuente A 12 To elaborate and validate a questionnaire on patient satisfaction with the follitropin alfa prefi lled pen, compared with previously used injectable gonadotropins, in women undergoing ovarian stimulation. METHODS: VENUsf questionnaire with 14 items was constructed after a four-stage process (concept identifi cation and item generation; item review by an expert on female infertility; patients interview; and editing of questionnaire according to interviews results) in which both experts on health outcomes research and fertility professionals and patients were involved. a post-authorization observational study (non-randomised patients, national setting) was undergone in order to validate the questionnaire. After assessing sample adequacy (Kaiser-Meyer-Olkin index and Bartlett's test of sphericity), Rasch analysis (infi t and outfi t statistics) provided a reduced version of the questionnaire. Its psychometric properties were assessed: feasibility (omitted response and time to fulfi l it), variability (fl oor and ceiling effects), validity (factor analysis and nonparametric tests) and reliability (Cronbach's alpha). RESULTS: Initial questionnaire (14 items and 6 additional questions) was answered by 91.1% of sample (n = 107) in an average of 5.04 minutes (SD = 3.3). Statistical correlation was observed between scores from two dimensions of questionnaire and overall treatment satisfaction, as well as variables Number of previous treatments, Time since last treatment and Minutes required to prepare pen. Rasch analyses yield 9 items in the fi nal version of the questionnaire. This process was confi rmed by sample adequacy (KMO = 0.72, statistically signifi cant value of Bartlett's test of sphericity) and reliability parameters (Cronbach's alpha = 0.78). CONCLU-SIONS: The reduced version of the questionnaire VENUsf a feasible, valid and reliable tool for assessing patient satifaction with follitropin alfa prefi lled pen in women undergoing ovarian stimulation.
PIH37 DISPENSED MEDICATIONS LABELING IN MALAYSIA: VIEWS FROM GENERAL PUBLIC
Al-Haddad M, Hassali MA Universiti Sains Malaysia, Penang, Malaysia OBJECTIVES: To assess the perceptions of the general public in Malaysia about the importance of drug labeling. METHODS: A cross sectional study using pre-validated questionnaire was undertaken with a convenient sample of general public in the State of Penang, Malaysia. All data was analyzed using SPSS for Windows version 12.0. Inferential statistics were used whenever appropriate at alpha value of 0.05 or less considered signifi cant. RESULTS: A total of 365 respondents had participated in the survey. Majority of them agreed that drug labeling is important to any person dispensing medicines (74.8%), caretakers (76.26%), health care professionals (77.8%) and patients (80.6%). Besides, they believed that it is important to ensure all drug labels are not vaguely claimed to improve quality of life (54.2%). Majority of respondents agreed that incorrect dosage instructions on the drug label would result in worsening the quality of life (73.2%). Majority of respondents (58.4%) believed that drug labeling is highly important to ensure safe and effective drug use. Majority also expected that all drug products and controlled medicines should be labeled with product name (97.5%), active ingredients (78%), date of manufacture and expiry (87%), and dosage
